For the last several months, we’ve talked to many people within the diabetes community and asked, “What more can we do?” based on the healthcare system Americans rely on today. These people face different challenges and situations and one solution can’t cover them all. While we continue to work with others in the US healthcare system for a longer-term solution, we feel the sense of urgency and anger from the community and want to do more both for those who have insurance and those who do not.

So, in addition to Novo Nordisk’s current affordability options on—including our Patient Assistance Programs that can offer free medicines to eligible patients, Novo Nordisk human insulin which has been available for $25/vial at Walmart and recently expanded to CVS Health and ESI, and our co-pay savings cards—Novo Nordisk will offer two additional options on January 2, 2020:

  • A $99.00 Cash Card Program for Analog Insulins:  As part of this program, people with diabetes can purchase up to three vials or two packs of FlexPen®/FlexTouch® pens of any combination of Novo Nordisk analog insulins (3000 – 3800 Units total depending on the brands) for a flat cost of $99.00. To put this in perspective, this amount of product should cover most patients’ monthly insulin needs. This program is being made available from the Novo Nordisk US affiliate Novo Nordisk Inc. (NNI)
  • Follow-On Insulin Brands (also known as an authorized generic): Follow-on brand versions of Novo Nordisk’s most-widely prescribed short-acting analog insulins will be made available from the newly established Novo Nordisk US affiliate Novo Nordisk Pharma Inc. (NNPI) at a 50 percent discount compared to the current list price of the branded versions.

More details are found in our press release and more specific details will be available at the time these offerings are launched. We believe these offerings represent helpful additions to our NovoCare® affordability program, especially for people with diabetes in high-deductible health plans or without insurance.

Although we hope this is a meaningful step, we recognize that it’s not the answer for everyone. We’ll continue to work toward longer-term reform and making it easier for people who need our help to get it. For instance, we support the recent IRS ruling that classifies diabetes medications as preventive care. This has the potential to help so many people with diabetes. We are actively requesting that insurance plan decision makers participate in this new rule.

In the meantime, anyone who needs help affording our medicines should visit for information about our Patient Assistance Programs, co-pay cards, and more, or call our Customer Care team at 1.800.727.6500.